Revvity
RVTY · What the business does, what can go wrong, and how options sellers approach it
What it does
Revvity is a life sciences and diagnostics company. It makes tools that researchers, drug developers and clinical labs use to study biology and test for disease. The company was previously known as PerkinElmer and adopted the Revvity name after selling off other businesses.
It reports in two broad areas. The life sciences side sells reagents, instruments and software to biopharma companies and academic labs. The diagnostics side focuses on immunodiagnostics and on newborn and reproductive health testing.
How it makes money
Revvity sells instruments, consumables such as reagents and test kits, software, and services. Consumables are bought repeatedly, which can make revenue steadier than one-time equipment sales. Instruments tend to be more sensitive to customer budgets. Its products are sold worldwide, with the US, Europe and China among the key markets.
Why investors own it
- Exposure to long-term demand for drug discovery, research and medical testing.
- A recurring mix of consumables, software and testing products alongside equipment.
- Diagnostics can be less tied to research funding cycles than the life sciences business.
- Geographic diversity across several regions.
What can go wrong
- Biopharma and academic spending can slow when funding tightens or customers cut budgets.
- Government research funding and policy changes can affect demand.
- Exposure to China brings trade, regulatory and local competition risks.
- Competition from larger, better-resourced rivals in life science tools and diagnostics.
- Healthcare reimbursement and regulation can change how diagnostic products are priced and approved.
- Acquisitions can bring integration risk and may not deliver what was expected.
What to watch
- Organic revenue growth by segment
- Consumables versus instrument demand
- Biopharma and academic customer spending trends
- Operating margin trends
- China demand and policy developments
- Free cash flow and capital allocation
- Management guidance changes
Options income angle
Options on RVTY are generally available across several expirations, but they are typically less liquid than those on large, heavily traded stocks. Bid-ask spreads can be wide, especially on strikes far from the current price. Implied volatility tends to rise ahead of quarterly earnings and when guidance or sector sentiment shifts, such as changes in biopharma spending or research funding.
One caution for premium sellers: an earnings-driven price gap can move the stock well past a short strike overnight, and thin liquidity can make adjusting or closing the position costly.
This is educational content, not investment advice.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 28, 2025, filed February 24, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Revvity grew revenue 4% in fiscal year 2025, but tariffs, currency moves and product mix pushed gross margin lower, and profit did not keep pace with sales. The company spent heavily on share repurchases, has a euro bond maturing in July 2026, and reports that one large goodwill balance has a limited cushion over its carrying value.
How the business did
- Revenue was $2,856.1 million, against $2,755.0 million the year before, an increase of 4%. About 1% of that came from favorable currency changes.
- Diagnostics revenue rose 5% to $1,424.9 million, led by Immunodiagnostics (up $41.3 million) and Reproductive Health (up $27.2 million). Life Sciences rose 2% to $1,431.1 million, driven by Software (up $35.6 million), while Life Sciences Solutions fell $3.1 million.
- Gross margin decreased 104 basis points to 54.8% (a basis point is one hundredth of a percentage point), mainly from tariffs, currency and mix. Operating margin fell only 10 basis points, helped by cost containment. Restructuring and other costs were $55.9 million, against $17.5 million, with severance affecting approximately 5% of the workforce.
- Net cash from continuing operations was $589.0 million, against $665.0 million. The company repurchased shares for $820.8 million and paid $32.8 million in dividends. It ended the year with cash and cash equivalents of $919.9 million.
Risks specific to this company
- U.S. funding and regulation: Customers include drug makers, labs and academic and government institutions. The filing says recent U.S. funding and regulatory changes have made them more cautious about buying instruments and consumables.
- Tariffs: Tariffs increased cost of revenue by approximately $25 million and reduced gross margin by approximately $20 million, mostly on products made in Europe and sold in the U.S. The company says its mitigation steps may not fully offset future tariffs.
- International and China exposure: Sales outside the United States were the majority of revenue. Diagnostics margins were hurt by China diagnostic testing policy changes, and slower collections in China weighed on cash flow.
- Goodwill: Net intangible assets were $9.0 billion. The Life Sciences Solutions unit, with goodwill of $4.5 billion, had a fair value that exceeded its carrying value by more than 10% but less than 20%. A miss on growth or discount-rate assumptions could force an impairment charge.
- Debt and covenants: The company calls its debt substantial. Its revolver and notes carry restrictions, including limits on dividends and buybacks. Losing its investment grade credit rating would raise borrowing costs and bring potentially tighter covenants.
- Single-source suppliers: Some critical materials and components come from limited or single suppliers, and supply contracts have no minimum purchase requirements.
What management is watching
- Management expects capital expenditures to increase in fiscal year 2026, to fund digital capabilities, product innovation and realigning production. Fiscal year 2026 will also have 53 weeks instead of 52.
- The 2026 Notes mature in July 2026. Management expects to repay them from cash on hand, the revolving credit facility, or both. The facility offers $1.5 billion of borrowing capacity through January 7, 2030.
- A new $1.0 billion repurchase program runs to October 22, 2027, with $879.5 million remaining at year end. The quarterly dividend is $0.07 per share, though the filing says the Board could reduce or eliminate it.
- Management points to gross margin, operating margin and segment operating margin as key measures. Segment operating margin was 32.0% in Life Sciences and 24.2% in Diagnostics. It cites productivity and cost containment initiatives as offsets to margin pressure.
- Management says its product range, market positions and scale support long-term growth, margin expansion and strong cash flow.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended October 4, 2026, filed November 10, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Revenue for the third quarter was $728.9 million, up 4%, as Life Sciences grew while Diagnostics shrank. Profit margins improved, helped by a better product mix and a benefit from restructuring (cost-cutting through layoffs and facility consolidation). Restructuring charges also rose, and the company repaid a large bond at maturity.
How the business did
- Revenue: Life Sciences revenue was $379.6 million, up 11%, driven by Life Sciences Solutions and Software. Diagnostics revenue was $349.3 million, down 2%, because Immunodiagnostics fell by $10.5 million, partly offset by Reproductive Health. Nine-month revenue was $2,169.7 million, up 4%. The filing notes that the nine-month figures include an extra fiscal week, because fiscal 2026 has 53 weeks.
- Margins: Gross margin rose to 57.4% from 53.6%, and operating margin rose to 13.1% from 11.7%. For the nine months, tariff refunds also helped. The company applied for $20.2 million of refunds after the Supreme Court ruled the International Emergency Economic Powers Act does not authorize tariffs. It books refunds as income only when paid.
- Costs: Restructuring and other costs were $28.4 million, up from $9.9 million. Severance actions in the quarter affected approximately 2% of the workforce.
- Cash and capital return: Operating cash flow for the nine months was $484.5 million, versus $407.0 million a year earlier. The company repaid its €500.0 million ($571.2 million) 2026 Notes at maturity. It bought back no shares in the quarter, with $792.7 million left on its repurchase authorization. It declared a quarterly dividend of $0.07 per share. Cash was $592.8 million.
What management is watching
- The company expects an effective tax rate, before one-time items, of approximately 20% for fiscal 2026.
- It has agreed to buy Human Cell Design for €45.0 million (approximately $52.3 million) in cash, plus up to €8.0 million (approximately $9.3 million) in contingent payments tied to revenue. Closing is expected in the fourth quarter, subject to regulatory approvals.
- Management cites cost containment, restructuring savings and product mix as margin drivers. It also flags spending on software, new products and digital investments. The MD&A gives no revenue outlook for the rest of the year.
- The company says its Board may reduce or eliminate the dividend to fund growth, repurchase shares or conserve cash.
New or changed risks
- China divestiture: The risk factors mention a recent definitive agreement to divest the Immunodiagnostics business in China. If the sale fails, the company warns of unexpected transaction costs, disruption and missed strategic goals.
- Acquisitions: The acquisition risk now cites the recent purchase of Advanced Chemistry Development Inc. It repeats the risks of integrating acquired businesses.
- Tariffs and conflicts: The company says it cannot predict the scope or timing of U.S. tariffs or retaliation. Its mitigation steps may not fully offset them. The supply chain risk now names the conflicts in Ukraine and Iran.
- Intangible assets: Net intangible assets, mostly goodwill from acquisitions, were $8.7 billion as of October 4, 2026. The company warns that a weak business outlook or failure to grow could force a write-down.
Follow RVTY in Kortex
The Kortex app shows RVTY's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.